Angiotensin-converting enzyme inhibitors in the treatment of hypertension

G. Mancia

Research output: Contribution to journalArticlepeer-review

Abstract

This article examines the evidence justifying the use of angiotensin-converting enzyme (ACE) inhibitors as first-line antihypertensive drugs. ACE inhibitors are as effective as traditional antihypertensive agents and, in addition, exert their blood-pressure-lowering effect with near optimal hemodynamic alterations. These drugs have a good tolerance and safety profile although they induce cough in an appreciable number of patients. They can he safely associated with other antihypertensive agents to provide therapeutic benefit in a large proportion of the hypertensive population. ACE inhibitors are contraindicated only in bilateral renal artery stenosis or stenosis of a single kidney. Although to date no prospective study has examined the ability of ACE inhibitors to reduce cardiovascular morbidity and mortality in hypertension, several features of these drugs suggest that this may be the case as several effects of ACE inhibitors in hypertension are potentially nephroprotective and cardioprotective.

Original languageEnglish
Pages (from-to)S1-S3
JournalJournal of Cardiovascular Pharmacology
Volume18
Issue number7
Publication statusPublished - 1991

Keywords

  • ACE inhibitors
  • Antihypertensive agents
  • Renal artery stenosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Angiotensin-converting enzyme inhibitors in the treatment of hypertension'. Together they form a unique fingerprint.

Cite this